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Protein kinasesDuring myocardial ischemia/reperfusion, mitochondria are both a source and a target of injury. In
cardioprotective maneuvers such as ischemic and pharmacological pre- and postconditioning mitochondria
have a decisive role. Since about 99% of themitochondrial proteins are encoded in the nucleus, deleterious and
protective mitochondrial effects most likely comprise the import of cytosolic proteins. The present review
therefore discusses the role of mitochondria in myocardial ischemia/reperfusion injury and protection from it,
focusing on some cytosolic proteins, which are translocated into mitochondria before, during, or following
ischemia/reperfusion. Both morphological and functional alterations are discussed at the level of the heart,
the cardiomyocyte and/or themitochondrion itself. This article is part of a Special Issue entitled: Mitochondria
and Cardioprotection.hondria and Cardioprotection.
engler).
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Mitochondria contain their own DNA as a small circular molecule
of about 16 kb. The mitochondrial DNA only encodes 2 rRNAs, 22
tRNAs, and 13 proteins which serve as subunits of the respiratory
chain. During evolution many mitochondrial genes have been
transferred to the cell nucleus and now the majority of mitochondrial
proteins is encoded in the nuclear DNA.
The development of mass spectrometry-based techniques allowed
the identiﬁcation and characterization of these nuclear-encoded
mitochondrial proteins. A recent large-scale analysis of the murine
cardiac proteome using gel-free shotgun sequencing of subcellular
protein fractions resulted in the identiﬁcation of about 4900 proteins
in total, of which around 650 proteins were allocated to the
mitochondrial matrix and around 850 to the mitochondrial mem-
branes [27]. In a recent study on puriﬁedmouse cardiac mitochondria,
940 distinct proteins were identiﬁed using liquid chromatography
tandem mass spectrometry (LC/MS/MS), of which 480 proteins were
not previously recognized as mitochondrial proteins by proteomic
proﬁling [138]. Of these 940 proteins, only 59 were classiﬁed as
proteins of “unknown function”. Around 80% of the 615 proteins of the
human heart mitochondrial proteome identiﬁed by matrix-assisted
laser desorption/ionization time of ﬂight (MALDI-TOF) and LC/MS/MS
analysis function in oxidative phosphorylation, RNA, DNA, and protein
synthesis, ion transport and metabolism; however, the function of
around 20% of the human mitochondrial proteins has not beendeﬁned yet [124]. A further identiﬁcation of the mitochondrial
proteome and the associated protein function will contribute to our
understanding of the importance of mitochondria for myocardial
morphology and function under physiological and pathophysiological
conditions, independent from and in addition to their utmost
importance in energy production.
2. Protein import into mitochondria
Since more than 99% of themitochondrial proteins are synthesized
in the cytosol, the majority of the mitochondrial proteins has to be
imported. Detailed information on the components and pathways of
the mitochondrial import machineries is summarized in recent
reviews [31,50].
In the cytosol, preproteins are kept soluble by interactions with
molecular chaperones such as heat shock protein 90 (Hsp90) or heat
shock cognate 70 (Hsc70). The chaperones guide the preproteins to
the mitochondrion, where they interact with the mitochondrial outer
membrane translocase (Tom) complex [51]. The Tom complex is the
main protein entry gate of the mitochondria. The proteins Tom20,
Tom22, and Tom70 function as presequence receptors and detect
mitochondrial targeting signals of cytosolic preproteins. Tom40 forms
the channel for preprotein import across the outer mitochondrial
membrane. Following passage of the Tom40-formed channel, differ-
ent complexes direct the preproteins to their ﬁnal destination in the
different mitochondrial compartments. The proteins of the translo-
case of the inner membrane (Tim) complex transport preproteins
across the inner membrane. To direct preproteins into the mitochon-
drial matrix, Tim23 interacts with the presequence associated motor
(Pam) complex. Most proteins without cleavable presequences are
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outer membrane via the topogenesis of mitochondrial outer mem-
brane β-barrel proteins/sorting and assembly machinery (Tob/Sam)
complex. Protein import into the intermembrane space is facilitated
by the Tim40/mitochondrial intermembrane space import and
assembly (Mia) complex. Alternatively, mitochondrial- or nuclear-
encoded proteins can be directed from the matrix to the inner
membrane by the oxidase assembly (Oxa) pathway.
Cleavable presequences, typically 5–20 amino acid residues in
length at the amino terminus of the preprotein, represent the classical
type of mitochondrial targeting signals. The presequence receptors of
the Tom complex contain receptor domains for the detection of
cytosolic presequences, which, upon interaction with the prese-
quence receptor, form an α-helical structure. Most of these pre-
sequences are removed in the mitochondrial matrix by mitochondrial
processing peptidases. A hydrophobic sorting signal adjacent to theα-
helical presequence induces the stop of the protein translocation
process in the inner membrane. Proteins with a destination at the
inner membrane are anchored, and inner membrane peptidases
cleave the sorting signal of the preproteins with a destination in the
intermembrane space. Several proteins, among them mostly outer
membrane proteins and proteins of the intermembrane space, contain
internal, non-cleavable targeting signals. These signals are neither
conserved in their location within the proteins nor in their amino acid
composition.
Taken together, translocation of nuclear-encoded proteins into
mitochondria is determined by an interplay of mitochondrial targeting
signals with different protein complexes of the import machinery.
3. Mitochondria in ischemia/reperfusion injury
During normoxia, mitochondria consume large amounts of oxygen
to produce ATP at complex V of the respiratory chain. When the heart
becomes ischemic, the electron ﬂow along the respiratory complexes
is inhibited and mitochondrial oxygen consumption as well as ATP
production decrease [18,77,101]. Instead, myocardial ATP produced in
the cytosol by anaerobic glycolysis is now consumed by mitochondria
to maintain their inner membrane potential. At reperfusion in still
viable cells, oxidative phosphorylation is restored, ATP production
increases and may contribute to the reestablishment of cellular ion
homeostasis. However, increased ATP production may paradoxically
also contribute to reperfusion injury. During ischemia, the cardio-
myocyte cytosol becomes overloaded with calcium (Ca2+). At
reperfusion, when ATP production is restored, Ca2+ is taken up into
the sarcoplasmic reticulum (SR) by the SR calcium ATPase. However,
once the SR is Ca2+ overloaded, it is once again released from the SR
resulting in high cytosolic Ca2+ concentrations; the repetition of this
process at early reperfusion has been termed “calcium oscillation”.
High cytosolic Ca2+ concentrations in the presence of ATP result in
hypercontracture of cardiomyocytes, membrane disruption and
subsequent necrosis [105].
Mitochondria also take up cytosolic Ca2+ by the Ca2+ uniporter. In
the presence of high cytosolic Ca2+ concentrations, mitochondriamight
become Ca2+ overloaded with the consequences outlined below [83].
Here, also intracellular communication between the sarcoplasmatic
reticulum and mitochondria seems to be involved [110].
Apart from ATP, mitochondria also generate reactive oxygen
species (ROS) [8,49,90]. Within mitochondria, ROS originate from
different sources, one of them is the respiratory chain itself, mainly
complexes I and III. Here, electrons from the electron transport chain
can be transferred to oxygen, which results in the formation of
superoxide anions. ROS are also produced by monoamine oxidases
located at the outer mitochondrial membrane, which transfer
electrons from amine compounds to oxygen leading to hydrogen
peroxide formation [52]. Furthermore, the cytosolic protein p66Shc
becomes phosphorylated under stress conditions and shuttles into themitochondrial intermembrane space, where it oxidizes reduced
cytochrome c resulting in peroxide formation [54].
ROS formation increases during ischemia [12,131], and a further
burst of ROS occurs in early reperfusion [73,101]. Increased ROS
formation is causally involved in cell death after ischemia/reperfusion
[1,12,75,106,128,131], and ROS scavenging at reperfusion reduces
reversible and irreversible cellular injury [130]. Accordingly, hearts
from p66Shc knockout mice are protected from ischemia/reperfusion
injury in vitro [30,47], and inhibition of monoamine oxidase reduces
infarct size following ischemia/reperfusion injury in vivo [13].
The burst of ROS at the onset of reperfusion facilitates opening of
the mitochondrial permeability transition pore (MPTP), a large
conductance pore in the inner mitochondrial membrane. MPTP
opening at reperfusion enhances inner mitochondrial membrane
permeability to solutes with molecular weights up to 1.5 kDa and
leads to mitochondrial depolarization and subsequently to ATP
depletion [46]. Mitochondrial matrix volume increases and induces
rupture of the outer mitochondrial membrane. This leads to loss of
pyridine nucleotides and thereby to the inhibition of electron ﬂow
along the protein complexes of the electron transport chain. MPTP
opening is facilitated by Ca2+ ions, inorganic phosphate and
mitochondrial depolarization, i.e., conditions occurring during ische-
mia and reperfusion [45,66]. In contrast, MPTP opening is delayed at
increasedmitochondrial membrane potentials, high concentrations of
protons, magnesium ions, adenine nucleotides, and nitric oxide
[45,132]. The traditional hypothesis that the MPTP is formed by the
voltage-dependent anion channel (VDAC) in the outer membrane, the
adenine nucleotide transporter (ANT) in the inner membrane, and
cyclophilin D in the matrix has recently been challenged, since
experiments on VDAC and ANT knockout mitochondria displayed
effective calcium-induced MPTP opening [6,74]. Knockout of cyclo-
philin D delays calcium-induced MPTP opening of isolated liver and
cardiac mitochondria [5,10] and protects ﬁbroblasts from H2O2-
induced loss of mitochondrial membrane potential [5]. However,
cyclophilin D-deﬁciency has no effect on MPTP opening in isolated
mitochondria in the presence of diamide, which acts through the
redox-sensitive dithiol [10], and in response to adenine nucleotides,
suggesting that theMPTP can also open in the absence of cyclophilin D
[10].
Whereas cardiomyocyte death after ischemia/reperfusion is
mainly necrotic, mitochondrial apoptotic pathways are also initiated
by ischemia/reperfusion. Loss of mitochondrial membrane potential
andmatrix swelling caused byMPTP opening induce the release of the
pro-apoptotic protein cytochrome c from the intermembrane space
into the cytosol, which ultimately leads to the activation of caspase-
mediated apoptosis [140].
Ischemia/reperfusion and cardioprotective interventions impact
on mitochondrial morphology and the inter-mitochondrial network,
i.e., fusion and ﬁssion [28,97]. Mitochondrial fusion proteins include
the outer membrane proteins mitofusin (Mfn) 1 and 2 and the inner
membrane protein optic atrophy protein 1 (Opa1). Mitochondrial
ﬁssion proteins are the dynamin-related protein 1 (Drp1), which is
recruited from the cytosol to the mitochondria, and the outer
membrane protein human mitochondrial ﬁssion protein 1 (hFis1)
(for a review, see [48]). Decreasing mitochondrial ﬁssion is cardio-
protective, since a Drp1 inhibitor reduces cardiomyocyte death
following ischemia/reperfusion both in vitro and in vivo [98].
Apart from its involvement in mitochondrial fusion, Mfn2 is also
localized at the contact sites between the mitochondria and the
endoplasmic reticulum and Mfn2 deﬁciency reduces mitochondrial
Ca2+ uptake by increasing the distance between the endoplasmic
reticulum and the mitochondria [44].
Release of ROS or pro-apoptotic factors from damaged mitochon-
dria enhances cardiomyocyte injury. Althoughmitochondrial fusion is
viewed as a mitochondrial repair mechanism, irreversibly damaged
mitochondria need to be removed by mitophagy and indeed, the
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tive [57].
Taken together, whereas ischemia and reperfusion damage
mitochondria (e.g., limited oxidative phosphorylation), mitochondria
themselves may contribute to myocardial injury (e.g., MPTP opening-
induced cell death) [65,66].
4. Mitochondrial proteins contributing to the cardioprotection by
pre- and postconditioning
Infarct size after ischemia/reperfusion can be reduced by cardio-
protective maneuvers such as ischemic pre- and postconditioning. In
ischemic preconditioning, infarct size following sustained ischemia
and reperfusion is decreased by preceding, non-lethal episodes of
ischemia/reperfusion [91], whereas in ischemic postconditioning, the
brief cycles of ischemia and reperfusion are employed at the
immediate onset of reperfusion [139]. Both pre- and postconditioning
can be mimicked pharmacologically. The signal transduction cascades
of these cardioprotective phenomena, especially that of precondition-
ing, have been extensively studied, and it has become clear that
different pathways ﬁnally target the mitochondria and that preser-
vation of mitochondrial function is central for cardioprotection
[19,63,66,89,99].
The proper analysis of the import of nuclear-encoded proteins into
the mitochondria after ischemia/reperfusion clearly depends on the
purity of the mitochondrial preparations. A crude mitochondrial
preparation can be obtained by differential centrifugation; however, a
pure mitochondrial preparation requires additional ultracentrifuga-
tion using sucrose- or Percoll-gradients. In most cases, the purity of
the mitochondrial preparations is demonstrated by the absence of
marker proteins of subcellular compartments in the mitochondrial
fraction by Western blot analysis. Using immuno-electron and
confocal microscopy, a direct mitochondrial localization can be
shown. In addition, proteins located in the inner mitochondrial
membrane or the mitochondrial matrix are detectable in mitochon-
drial subfractions, in which proteins of the outer membrane and the
intermembrane space are removed, whereas contaminating proteins
are no longer traceable in these preparations [21,107].
In the present review, we will discuss nuclear-encoded proteins,
which are imported into the mitochondria and exert their cardiopro-
tective function by modulating mitochondrial structure and/or
function.
4.1. Proteins of the mitochondrial import machinery
Under conditions that require mitochondrial biogenesis and hence
increased levels of mitochondrial proteins, protein import into the
mitochondria is enhanced [122]. Mitochondrial protein import is
partially dependent on the contents of proteins constituting the
import machinery; accordingly, overexpression of the presequence
receptor Tom20 increases and inhibition of Tom20 decreases
mitochondrial protein import [60,86]. In pig myocardium, the
mitochondrial Tom20 content during reperfusion is reduced by
ischemia and ischemic preconditioning preserves the mitochondrial
Tom20 content. Ischemic preconditioning has, however, no effect on
the amounts of Tom40 and Tim23 [17]. The preservation of the Tom20
content by preconditioning may contribute to the maintenance of
mitochondrial proteins needed for proper post-ischemic mitochon-
drial function.
Mitochondrial heat shock protein 70 (Hsp70) in the matrix
interacts with Tim44 and thereby generates a “pulling” force, which
supports unfolding of proteins during translocation [133]. Adenoviral
transfection of neonatal cardiomyocytes with mitochondrial Hsp70
increases the activities of protein complexes of the electron transport
chain and cellular ATP content, and it improves cell viability following
simulated ischemia and reoxygenation [135]. Protein import intomitochondria is terminated by proper protein folding and Hsp60 and
Hsp10 are the major sites of protein folding in mitochondria.
Overexpression of Hsp60 and Hsp10 confers protection in isolated
cardiomyocytes during simulated ischemia [68,76] and increases the
activities of complexes of the electron transport chain [79]. Transfec-
tion of cells with amutant Hsp10, which renders the protein incapable
of interacting with Hsp60, increases cell death after simulated
ischemia/reoxygenation and decreases the activity of complex II of
the electron transport chain [78].
Taken together, enhanced contents of proteins of the import
machinery involved in presequence recognition, membrane transloca-
tion and protein folding (as achieved for example by preconditioning)
increase the activities of respiratory chain complexes and preserve
viability of cardiomyocytes following ischemia/reperfusion.
4.2. Proteins involved in mitochondrial energetics
In isolated rat hearts undergoing ischemia/reperfusion without and
with ischemic preconditioning [136], the majority of proteins which
differ in content contribute to mitochondrial energetics such as
oxidative phosphorylation, β-oxidation and ATP production. Precondi-
tioning enhances the levels of cytochrome c oxidase subunit VIb in
mitochondrial supercomplexes formed by the proteins of the electron
transport chain, and maintenance of the supercomplexes is important
for proper mitochondrial respiratory function [108]. The precondition-
ing-induced alteration in mitochondrial protein content may alter the
composition of the supercomplexes of the electron transport chain
proteins and may thereby impact on mitochondrial function. Pharma-
cological preconditioning of isolated cardiomyocytes with adenosine or
diazoxide increases the amounts of 19mitochondrial proteins in total, of
which 10 proteins relate to the tricarboxylic acid cycle and oxidative
phosphorylation [3]. The small number of affected proteins suggests a
very speciﬁc response to pharmacological preconditioning.
Ischemic and pharmacological preconditioning alters the amounts
and the posttranslational modiﬁcations of mitochondrial proteins,
especially of proteins important for mitochondrial energetics.
4.3. Mitochondrial protein kinases
In the signal transduction cascades of pre- and postconditioning,
cytosolic protein kinases are activated via receptor-initiated pathways
or via signals originating within mitochondria, e.g., ROS [4,42,65].
However, also shuttling of protein kinases into mitochondria or
changes in the activity of mitochondrial protein kinases are initiated
by ischemia/reperfusion and/or cardioprotective interventions.
4.3.1. Protein kinase C epsilon (PKCε)
The ten members of the PKC protein family are classiﬁed into the
conventional isoenzymes (PKCα, PKCβI, PKCβII, and PKCγ), the novel
isoenzymes (PKCδ, PKCε, PKCη, and PKCθ) and the atypical iso-
enzymes (PKCζ and PKCλ (mouse, the human homologue is termed
PKCι) according to their requirements for the second messengers
diacylglycerol and Ca2+ [92]. Despite a high structural homology, the
function of the PKC isoforms is quite diverse, e.g., PKCδ enhances and
PKCε reduces irreversible myocardial injury in rodents following
ischemia/reperfusion [33,69,115]. However, in larger mammals such
as pigs, PKCα seems to be the isoform involved in ischemia/
reperfusion injury and protection from it [113]. In rodents, PKCε is
an important signaling element of ischemic preconditioning; phar-
macological inhibition of PKCε [59,80] or genetic deletion of the gene
encoding PKCε abolishes ischemic preconditioning's cardioprotection
[111]. Also, the cardioprotection by ischemic postconditioning was
lost in isolated rat hearts treated with a speciﬁc PKCε inhibitor [137].
Upon a preconditioning stimulus, PKCε translocates from the cytosol
to the particulate fraction [96,103,129], but also to the mitochondria
[96]. Whether or not postconditioning also induces mitochondrial
1289K. Boengler et al. / Biochimica et Biophysica Acta 1813 (2011) 1286–1294PKCε translocation is unknown at present. Mitochondrial PKCε is
located within the intermembrane space and associated with the
inner mitochondrial membrane, but the presence of a second PKCε
pool within the matrix has been suggested [36]. PKCε is imported into
mitochondria via Hsp90 and the presequence receptor Tom20 [29].
Pharmacological inhibition of Hsp90 by geldanamycin reduces the
ischemia/reperfusion-induced mitochondrial translocation of PKCε
and increased necrotic cell death. On the other hand, stimulation of
the PKCε/Hsp90 interaction using the novel PKCε activating peptide
ψεHsp90 enhances the mitochondrial PKCε content and decreases
ischemia/reperfusion injury both in vitro and in vivo [29], demon-
strating the importance of mitochondrial PKCε for cell survival.
Within mitochondria, PKCε has several target proteins, and one of
them is mitogen activated protein kinase (MAP kinase) [7]. Signaling
modules of mitochondrial PKCε and the MAP kinase extracellular
signal-regulated kinase (ERK) induce the phosphorylation and
inactivation of the pro-apoptotic protein Bad [7]. PKCε also targets
aldehyde dehydrogenase [34], which contributes to cardioprotection
by inhibition of toxic aldehyde formation [32]. Preconditioning
increases the activity of cytochrome c oxidase, which plays a role in
the maintenance of the proton gradient along the inner mitochondrial
membrane and the generation of ATP; accordingly, there is increased
co-immunoprecipitation of PKCε with the cytochrome c oxidase
subunit IV [61]. The interaction of PKCε with connexin 43 [109] and
the role of PKCε in regulating opening of the mitochondrial ATP-
dependent potassium channel (mitoKATP channel) will be discussed in
detail below (see paragraph 4.4).
Taken together, PKCε is important for the cardioprotection by
ischemic pre- and postconditioning. Speciﬁcally mitochondrial PKCε
contributes to cardioprotection by regulating the activity of several
mitochondrial proteins. Whether the PKC isoform required for
cardioprotection is species-dependent remains to be elucidated.
4.3.2. Glycogen synthase kinase 3 β (GSK3β)
Glycogen synthase kinase 3 β (GSK-3β) is important for various
cellular functions, including glycogen metabolism, gene expression,
and cell survival. The activity of the protein is regulated via
phosphorylation; the phosphorylation of GSK3β at serine 9 renders
the protein inactive. Pharmacological inhibition of GSK3β either
before ischemia or before reperfusion reduces ischemia/reperfusion
injury [55,93,125]. Both ischemic preconditioning [93,125] and
ischemic postconditioning [123] are associated with enhanced
GSK3β phosphorylation in rodent hearts. In mice, in which serine 9
is replaced by alanine to render GSK3β insensitive to phosphorylation,
infarct size reduction by ischemic postconditioning is lost [55]. In
contrast, both ischemic pre- and postconditioning efﬁciently reduce
infarct size in mice with inactive phosphorylation sites at serine 9 in
GSK3β and serine 21 in the highly homologous isoform GSK3α,
demonstrating that GSK3 phosphorylation may be dispensable for
cardioprotection [95]. The divergent ﬁndings may be related to
different genetic mouse strains: while Gomez et al. investigated mice
in which mutated GSK3β was overexpressed and “endogenous”
GSK3β could still be inhibited [55], Nishino et al. analyzedmice with a
targeted knockin of noninhibitable GSK3α and GSK3β [95]. Support-
ing a highly variable role of GSK3β for cardioprotection, ischemic
postconditioning in pigs did not increase GSK3β phosphorylation over
that by reperfusion per se [116].
If protective, the effects of GSK3β involve mitochondrial structure
and proteins, e.g., inhibition of MPTP opening [71,72] and control of
mitochondrial adenine nucleotide transport through the outer
mitochondrial membrane [43]. Since GSK3β is mainly localized in
the cytosol but targets mitochondrial proteins, attention has been
directed to the presence and action of GSK3β within mitochondria.
Ischemia/reperfusion increases the content of total and phosphory-
lated GSK3β in mitochondria of isolated rat hearts and enhances the
protein–protein interaction between GSK3β and VDAC or ANT [94]. Inrat myocardium, the phosphorylation status of mitochondrial GSK3β
closely correlates with the Ca2+ concentration needed to induceMPTP
opening, suggesting that mitochondrial and not cytosolic GSK3β is
involved in cardioprotection [85]. However, translocation and
phosphorylation of GSK3β to/in mitochondria were not affected by
ischemic preconditioning in isolated rat hearts [35]. In contrast,
ischemic postconditioning was associated with enhanced mitochon-
drial contents of both total and phosphorylated GSK3β in isolated rat
hearts [102].
In summary, whereas data on the role of GSK3β in cardioprotec-
tion using genetic models revealed contradictory results, pharmaco-
logical inhibition of GSK3β clearly abolishes cardioprotection.
However, further studies are needed to distinguish between the
effects of cytosolic and mitochondrial GSK3β and to speciﬁcally
characterize the role of mitochondrial GSK3β in cardioprotection.
4.3.3. Pim-1
Pim-1 is a serine/threonine protein kinase, which belongs to the
family of calmodulin-dependent protein kinases. The mitochondrial
content of Pim-1 is enhanced following ischemia/reperfusion in vitro,
and mitochondria isolated from hearts of Pim-1 overexpressing mice
are more resistant to Ca2+-induced swelling than mitochondria from
wild-type mice [25]. Genetic Pim-1 ablation increases myocardial
infarct size after ischemia/reperfusion in vivo [88] and pharmacolog-
ical Pim-1 inhibition abrogates the cardioprotection by ischemic
preconditioning [120].
With Pim-1, a novel protein kinase has been identiﬁed to be
increased in mitochondria after ischemia/reperfusion. Up to now,
information on mitochondrial Pim-1 in ischemia/reperfusion is scarce
and it is unclear whether or not pre- and/or postconditioning impacts
on the mitochondrial contents of Pim-1.
4.4. Signal transducer and activator of transcription 3 (STAT3)
STAT (signal transducer and activator of transcription) proteins
transduce stress signals from the plasma membrane to the nucleus,
thereby acting as signaling molecules and transcriptional regulators
[20]. Myocardial STAT3 is central for the cardioprotection by ischemic
pre- and postconditioning [15,53,56,117,121]. The localization of
STAT3 is not restricted to the cytosol and the nucleus; the protein is
also detected in mitochondria [58,134], predominantly in the
mitochondrial matrix [21]. Both genetic reduction and pharmacolog-
ical inhibition of mitochondrial STAT3 reduce ADP-stimulated
respiration of myocardial mitochondria [21,134]. In addition to its
impact on oxygen consumption, mitochondrial STAT3 inhibits
calcium induced MPTP opening [21]. Despite the co-immunoprecip-
itation of STAT3 with cyclophilin D, cyclophilin D functions down-
stream of STAT3; accordingly, the cyclophilin D inhibitor cyclosporine
A reduces infarct size to a similar extent in wild-type and STAT3-
knockout mice in vivo [21].
The important role of STAT3 in cardioprotection may be in part
mediated by its effects onmitochondrial respiration andMPTP opening.
However, whether or not ischemic pre- and postconditioning induce a
translocation of STAT3 into mitochondria and impact on the activity/
phosphorylation of mitochondrial STAT3 is unclear at present.
4.5. Connexin 43
Cardioprotection by ischemic and pharmacological precondition-
ing is dependent on the amount of connexin 43 (Cx43); accordingly,
infarct size reduction by the above interventions is lost in heterozy-
gous Cx43-deﬁcient mice [64]. Cx43 is the predominant protein of
ventricular gap junctions, which regulate electrical cell coupling in the
myocardium. Gap junctions are formed by two opposing hemichan-
nels, each consisting of six Cx43 proteins forming a ring-like structure
(for a review, see [112,118]). Cx43 contains 4 transmembrane
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amino- and carboxytermini. Several phosphorylation sites are located
within the carboxyterminus, and Cx43 is the target of different
kinases, among them protein kinase A (PKA), PKC, and MAP kinases
(for a review, see [119]).
In addition to its localization at the plasmamembrane, Cx43 is also
present at the inner membrane of cardiomyocyte subsarcolemmal
mitochondria [16,24,107]. The pathway by which Cx43 is imported
into mitochondria involves Hsp90 and Tom20 [107]. Since inhibition
of Hsp90 by geldanamycin reduces the mitochondrial Cx43 content in
hearts perfused under normoxic conditions, it is possible that Cx43 is
continuously imported into mitochondria. Whether the half life of
mitochondrial Cx43 is similar to that of gap junctional Cx43 (about
90 min [11]) is unknown at present. Within mitochondria, Cx43 co-
immunoprecipitates with GSK3β [112].
Stimulation of mitochondrial potassium inﬂux via the – not yet at
the molecular level characterized – ATP-dependent mitochondrial
potassium channel (mitoKATP channel) is cardioprotective [36,38],
and activation of the mitoKATP channel is mediated by mitochondrial
PKCε [37,70]. Both genetic reduction and pharmacological inhibition
of Cx43 decrease the mitochondrial potassium inﬂux [87] and reduce
the open probability of the mitoKATP channel in response to the
mitoKATP opener diazoxide [109]. However, since the open probability
of the channel is not dependent on Cx43 under basal conditions, it is
unlikely that Cx43 represents the pore forming unit of the mitoKATP
channel [109]. Mitochondrial PKCε phosphorylates Cx43 and the
PKCε-mediated activation of the mitoKATP channel requires Cx43
[109]. Opening of the mitoKATP channel contributes to cardioprotec-
tion via the formation of small amounts of ROS, which function as
trigger molecules of preconditioning [2,100]. Cardiomyocytes from
heterozygous Cx43-deﬁcient mice do not form sufﬁcient amounts ofFig. 1.Mitochondrial Cx43 content and phosphorylation induced by ischemic postcondition
serine 368 (Cx43 Ser368) on mitochondrial proteins isolated from the ischemic anterior
ischemia and 10-min reperfusion without (isch/rep) and with (iPoco) ischemic postcondit
superoxide dismutase (MnSOD) was used for normalization of Cx43 immunoreactivities.
sarcolemmal marker protein Na+/K+-ATPase. B: Bar graphs represent the ratios of the immu
of MnSOD) in the AW over that in the PW of mice undergoing ischemia/reperfusion
immunoreactivities of mitochondrial total Cx43 (normalized to that of MnSOD) in the AW
postconditioning.ROS in response to diazoxide and accordingly have no infarct size
reduction after ischemia/reperfusion in vivo [64].
Ischemic preconditioning increases the amount of mitochondrial
Cx43 after short preconditioning cycles of ischemia/reperfusion in rat
hearts in vitro and after sustained ischemia in pig hearts in vivo [16].
In pig myocardium, ischemia/reperfusion is associated with increased
dephosphorylation of mitochondrial Cx43, and ischemic precondi-
tioning preserves Cx43 phosphorylation at the epitope Ser368 [126].
However, enhanced mitochondrial Cx43 content following precondi-
tioning is no prerequisite for cardioprotection. It is rather the decrease
of Cx43 below a certain threshold level which must be avoided to
preserve the protection of the myocardium by preconditioning. In rat
hearts in vitro, diazoxide reduces infarct size without impact on the
mitochondrial Cx43 content. In contrast, geldanamycin reduces the
amount of mitochondrial Cx43 and abolishes the cardioprotection by
diazoxide in rat hearts [107]. In bone marrow derived stem cell
antigen-1 (Sca-1)-positive stem cells, preconditioning with insulin-
like growth factor-1 (IGF-1) is associatedwith enhanced translocation
of Cx43 to the inner mitochondrial membrane [81]. Mitochondria-
speciﬁc overexpression of Cx43 in Sca-1 positive cells reduces
apoptosis and necrosis by oxygen glucose deprivation [82].
The role of mitochondrial Cx43 in ischemic postconditioning has
not been characterized in detail up to now. Penna and coworkers
demonstrated decreased amounts of total Cx43 in mitochondria,
which were isolated from postconditioned (5 cycles of 10 s ischemia
and reperfusion each) rat hearts undergoing 30 min ischemia and
120 min reperfusion in vitro [102]. The reduced amounts of total Cx43
were paralleled by reduced amounts of Cx43 phosphorylated at
Ser368. We have investigated the Cx43 content in mitochondria from
mouse hearts undergoing 30 min ischemia and 10 min reperfusion
without and with ischemic postconditioning by 3 cycles of 10 sing. A: Western blot analysis was performed for total Cx43 and Cx43 phosphorylated at
wall (AW) and control posterior wall (PW) from wild-type mice undergoing 30-min
ioning. Right ventricular (RV) total proteins were used as positive control, manganese
The purity of the mitochondrial preparations is demonstrated by the absence of the
noreactivities of mitochondrial Cx43 phosphorylated at serine 368 (normalized to that
alone or with ischemic postconditioning. C: Bar graphs represent the ratios of the
over that in the PW of mice undergoing ischemia/reperfusion alone or with ischemic
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ing increased both the level of total Cx43 and of Cx43 phosphorylated
at Ser368 (Fig. 1). However, changes in the amount of total Cx43 or
phosphorylated Cx43 may be an epiphenomenon associated with
ischemic postconditioning, since ischemic postconditioning reduces
infarct size in heterozygous Cx43-deﬁcient hearts to a similar extent
as in wild-type hearts [67].
Taken together, mitochondrial Cx43 is important for ischemic
preconditioning via modulation of the opening of mitoKATP channels
and subsequent ROS formation. Physiological amounts of mitochondrial
Cx43 are important for effective cardioprotection by ischemic and phar-
macological preconditioning but most likely not by postconditioning.
5. Mitochondrial protein import under
pathophysiological conditions
An interaction ofmitochondrial proteins encoded in the nucleus and
in the mitochondria is necessary for proper mitochondrial function and
defective import of mitochondrial proteins causes mitochondrial
dysfunction. The protein import into mitochondria can be impaired by
mutations in DNA encodingmitochondrial target sequences or proteins
of the import machinery. In addition, differential expression of genes
encoding proteins involved in mitochondrial protein import or folding
can alter protein import and thereby cause various diseases (for a
review, see [84]).
With aging, the transcription of genes encoding proteins with
different functions – among them subunits of the electron transport
chain [14] – is reduced, contributing to the development of mitochon-
drial dysfunction (for a review, see [23]). The amounts of nuclear-
encoded mitochondrial proteins which are important for cardioprotec-
tion are also affected by age [23]. For example, the amounts of Cx43 andPTP
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+ CytCp66Shc
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Fig. 2. Mitochondrial factors and proteins involved in myocardial ischemia/reperfusion inju
take up Ca2+. Mitochondrial Ca2+-overload at reperfusion induces mitochondrial permeabi
amounts of reactive oxygen species (ROS), which function as trigger molecules of preconditio
(KATP). KATP opening is regulated by protein kinase C epsilon (PKCε) via phosphorylation of
transport chain (ETC), by p66Shc, and/or by monoamine oxidases (MAO) modify proteins (ox
and the endoplasmic/sarcoplasmic reticulum, such as mitofusin 2 (Mfn2), dynamin-related
and structure and thereby enhance cell death. Furthermore, ROS facilitate PTP opening via tra
by glycogen synthase kinase 3 β (GSK3β). The role of mitochondrial signal transducer and act
more detail.STAT3 are reduced both in ventricular total protein extracts and in
mitochondria isolated from aged mice [21,22]. Since both proteins co-
immunoprecipitate with the presequence receptor Tom20, the de-
creased mitochondrial Tom20 content in mitochondria isolated from
aged mouse hearts may – at least in part – contribute to the reduced
mitochondrial contents of Cx43 and STAT3 [22]. However, the
mitochondrial import of precursor proteins obtained by in vitro
transcription is not impaired in aged myocardium, and the amounts of
the matrix chaperones Hsp70 and Hsp60 are not altered in aged hearts
[39]. Therefore, the reducedmitochondrial contents of proteins involved
in cardioprotection might be due to a combination of altered gene
transcription and mitochondrial protein import.
Mitochondrial dysfunction is associated with diabetes mellitus
types 1 and 2 [26,41,114], and the mitochondrial proteome changes
with diabetes. For example, proteins important for β-oxidation are
upregulated at 1 and 4 weeks after induction of diabetes type 1 by the
injection of streptozotocin (Stz) [127]. One week after Stz injection,
the mitochondrial amounts of Hsp60 and Hsp70 are reduced [127].
Reduced amounts of cardiac mitochondrial Hsp70 are also detected
5 weeks after Stz injection [9], but not 8 weeks after Stz treatment
[62]. The decrease of mitochondrial Hsp70 5 weeks after Stz injection
is more pronounced in mitochondria located between the myoﬁbrils
(interﬁbrillar mitochondria, IFM) than in mitochondria present
beneath the sarcolemma (subsarcolemmal mitochondria, SSM), and
it is associated with reduced mitochondrial protein import [9].
Similarly, mitochondrial Hsp70 is downregulated in SSM in a type 2
model of diabetes in mice with a mutated leptin receptor [40].
Taken together, the mitochondrial proteome is altered under
pathophysiological conditions, and these changes may be due to a
combination of differential expression of nuclear-encodedmitochondrial
proteins and alterations of the mitochondrial import machinery itself.GSK
3β
ox
th
Drp1
ox
CytC
 Reticulum 
mitochondrial-ER/SR
interaction
fusion/fission
KATP K+
Cx43
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ry. During ischemia, cardiomyocytes are overloaded with Ca2+, and mitochondria can
lity transition pore (PTP) opening and thereby necrotic and apoptotic cell death. Small
ning, are generated by opening of themitochondrial ATP-dependent potassium channel
connexin 43 (Cx43). Excessive amounts of ROS, produced by a dysfunctional electron
) involved in mitochondrial network formation and interaction between mitochondria
protein 1 (Drp1), optic atrophy protein 1 (Opa1), and damage mitochondrial proteins
nslocation of cyclophilin D (CypD) from the matrix to the PTP. PTP opening is facilitated
ivator of transcription 3 (STAT3) in themitochondrial matrix needs to be investigated in
1292 K. Boengler et al. / Biochimica et Biophysica Acta 1813 (2011) 1286–12946. Conclusion
Mitochondria are both a target and a source of ischemia/reperfusion
injury, and the cardioprotective mechanisms of ischemic and pharma-
cologicalpre- andpostconditioningdecisively involve themitochondria.
To allow for cardioprotection, several proteins have to be imported into
the mitochondria, and the proteins of the mitochondrial import
machinery itself contribute to cardioprotection. However, detailed
information on the molecular identity of the proteins imported into
mitochondria, the regulation of the mitochondrial import machinery
itself, and putative interrelations between the translocated proteins
upon a cardioprotective stimulus is not available up to now. Therefore,
the identiﬁcation of common denominators of the signaling pathways
inﬂuencing the import of proteins into mitochondria after ischemia/
reperfusion is challenging at present. In contrast to the sparse
information on how mitochondrial protein import is regulated by
cardioprotective stimuli, the impact of cardioprotective maneuvers on
mitochondrial function is more explicitly characterized, and a scheme
on the role of mitochondria in ischemia/reperfusion injury and in
cardioprotection is demonstrated in Fig. 2. Encouraging clinical data
suggest that patients with acutemyocardial infarction also beneﬁt from
preserved mitochondrial function [104], thereby emphasizing the
importance of mitochondria as therapeutical targets to limit ischemia/
reperfusion injury.
7. Sources of funding
K.B. (BO 2955/1-1), G.H. (He1320/18-1), and R.S. (Schu843/7-2)
are recipients of grants from the German Research Foundation.
References
[1] V.J. Adlam, J.C. Harrison, C.M. Porteous, A.M. James, R.A. Smith, M.P. Murphy, I.A.
Sammut, Targeting an antioxidant to mitochondria decreases cardiac ischemia–
reperfusion injury, FASEB J. 19 (2005) 1088–1095.
[2] A. Andrukhiv, A.D. Costa, I.C. West, K.D. Garlid, Opening mitoKATP increases
superoxide generation from complex I of the electron transport chain, Am. J.
Physiol. Heart Circ. Physiol. 291 (2006) H2067–H2074.
[3] D.K. Arrell, S.T. Elliott, L.A. Kane, Y. Guo, Y.H. Ko, P.L. Pedersen, J. Robinson, M.
Murata, A.M. Murphy, E. Marban, J.E. van Eyk, Proteomic analysis of
pharmacological preconditioning: novel protein targets converge to mitochon-
drial metabolism pathways, Circ. Res. 99 (2006) 706–714.
[4] C.P. Baines, M. Goto, J.M. Downey, Oxygen radicals released during ischemic
preconditioning contribute to cardioprotection in the rabbit myocardium, J. Mol.
Cell. Cardiol. 29 (1997) 207–216.
[5] C.P. Baines, R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, M.A. Hambleton, E.W.
Brunskill, M.R. Sayen, R.A. Gotlieb, G.W. Dorn II, J. Robbins, J.D. Molkentin, Loss of
cyclophiin D reveals a critical role for mitochondrial permeability transition in
cell death, Nature 434 (2005) 658–662.
[6] C.P. Baines, R.A. Kaiser, T. Sheiko, W.J. Craigen, J.D. Molkentin, Voltage-
dependent anion channels are dispensable for mitochondrial-dependent cell
death, Nat. Cell Biol. 9 (2007) 550–555.
[7] C.P. Baines, J. Zhang, G.-W. Wang, Y.-T. Zheng, J.X. Xiu, E.M. Cardwell, R. Bolli, P.
Ping, Mitochondrial PKCe and MAPK form signaling modules in the murine
heart, Circ. Res. 90 (2002) 390–397.
[8] R.S. Balaban, S. Nemoto, T. Finkel, Mitochondria, oxidants, and aging, Cell 120
(2005) 483–495.
[9] W.A. Baseler, E.R. Dabkowski, C.L. Williamson, T.L. Croston, D. Thapa, M.J. Powell,
T.T. Razunguwa, J.M. Hollander, Proteomic alterations of distinct mitochondrial
subpopulations in the type 1 diabetic heart: contribution of protein import
dysfunction, Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010)8 doi:10.1152/
ajpregu.00423.2010.
[10] E. Basso, L. Fante, J. Fowlkes, V. Petronilli, M.A. Forte, P. Bernardi, Properties of the
permeability transition pore in mitochondria devoid of Cyclophilin D, J. Biol.
Chem. 280 (2005) 18558–18561.
[11] M.A. Beardslee, J.G. Laing, E.C. Beyer, J.E. Safﬁtz, Rapid turnover of connexin43 in
the adult rat heart, Circ. Res. 83 (1998) 629–635.
[12] L.B. Becker, T.L. Vanden Hoek, Z.-H. Shao, C.-Q. Li, P.T. Schumacker, Generation of
superoxide in cardiomyocytes during ischemia before reperfusion, Am. J. Physiol.
277 (46) (1999) H2240–H2246.
[13] P. Bianchi, O. Kunduzova, E. Masini, C. Cambon, D. Bani, L. Raimondi, M.-H.
Seguelas, S. Nistri, W. Colucci, N. Leducq, A. Parini, Oxidative stress by
monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis
by serotonin and postischemic myocardial injury, Circulation 112 (2005)
3297–3305.[14] N. Bodyak, P.M. Kang, M. Hiromura, I. Sulijoadikusumo, N. Horikoshi, K. Khrapko,
A. Usheva, Gene expression proﬁling of the aging mouse cardiac myocytes,
Nucleic Acids Res. 30 (2002) 3788–3794.
[15] K. Boengler, A. Buechert, Y. Heinen, C. Roeskes, D. Hilﬁker-Kleiner, G. Heusch, R.
Schulz, Cardioprotection by ischemic postconditioning is lost in aged and STAT3-
deﬁcient mice, Circ. Res. 102 (2008) 131–135.
[16] K. Boengler, G. Dodoni, A. Rodriguez-Sinovas, A. Cabestrero, M. Ruiz-Maena, P.
Gres, I. Konietzka, C. Lopez-Iglesias, D. García-Dorado, G. Heusch, R. Schulz,
Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic
preconditioning, Cardiovasc. Res. 67 (2005) 234–244.
[17] K. Boengler, P. Gres, A. Cabestrero, M. Ruiz-Meana, D. Garcia-Dorado, G. Heusch,
R. Schulz, Prevention of the ischemia-induced decrease in mitochondrial Tom20
content by ischemic preconditioning, J. Mol. Cell. Cardiol. 41 (2006) 426–430.
[18] K. Boengler, P. Gres, G. Dodoni, I. Konietzka, L.F. Di, G. Heusch, R. Schulz,
Mitochondrial respiration and membrane potential after low-ﬂow ischemia are
not affected by ischemic preconditioning, J. Mol. Cell. Cardiol. 43 (2007) 610–615.
[19] K. Boengler, G. Heusch, R. Schulz, Mitochondria in postconditioning, Antioxid.
Redox. Signal. (2010)8 DOI:10.1089./ars.2010.3309.
[20] K. Boengler, D. Hilﬁker-Kleiner, H. Drexler, G. Heusch, R. Schulz, The myocardial
JAK/STAT pathway: from protection to failure, Pharmacol. Therap. 120 (2008)
172–185.
[21] K. Boengler, D. Hilﬁker-Kleiner, G. Heusch, R. Schulz, Inhibition of permeability
transition pore opening by mitochondrial STAT3 and its role in myocardial
ischemia/reperfusion, Basic Res. Cardiol. 105 (2010) 771–785.
[22] K. Boengler, I. Konietzka, A. Buechert, Y. Heinen, D. Garcia-Dorado, G. Heusch, R.
Schulz, Loss of ischemic preconditioning's cardioprotection in agedmouse hearts
is associated with reduced gap junctional and mitochondrial levels of connexin
43, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1764–H1769.
[23] K. Boengler, R. Schulz, G. Heusch, Loss of cardioprotection with ageing,
Cardiovasc. Res. 83 (2009) 247–261.
[24] K. Boengler, S. Stahlhofen, A. van de Sand, P. Gres, M. Ruiz-Meana, D. Garcia-
Dorado, G. Heusch, R. Schulz, Presence of connexin 43 in subsarcolemmal, but
not in interﬁbrillar cardiomyocyte mitochondria, Basic Res. Cardiol. 104 (2009)
141–147.
[25] G.A. Borillo, M. Mason, P. Quijada, M. Volkers, C. Cottage, M. McGregor, S. Din, K.
Fischer, N. Gude, D. Avitable, S. Barlow, A.B. Gustafsson, C. Glembotski, R.A.
Gottlieb, J.H. Brown, M.A. Sussman, Pim-1 kinase protects mitochondrial
integrity in cardiomyocytes, Circ. Res. 106 (2010) 1265–1274.
[26] S. Boudina, S. Sena, H. Theobald, X.M. Sheng, J.J. Wright, X.X. Hu, S. Aziz, J.I.
Johnson, H. Bugger, V.G. Zaha, E.D. Abel, Mitochondrial energetics in the heart in
obesity-related diabetes—direct evidence for increased uncoupled respiration
and activation of uncoupling proteins, Diabetes 56 (2007) 2457–2466.
[27] N. Bousette, T. Kislinger, V. Fong, R. Isserlin, J.A. Hewel, A. Emili, A.O. Gramolini,
Large-scale characterization and analysis of the murine cardiac proteome, J. Prot.
Res. 8 (2009) 1887–1901.
[28] N.R. Brady, A. Hamacher-Brady, R.A. Gottlieb, Proapoptotic BCL-2 family
members and mitochondrial dysfunction during ischemia/reperfusion injury, a
study employing cardiac HL-1 cells and GFP biosensors, Biochim. Biophys. Acta
1757 (2006) 667–678.
[29] G.R. Budas, E.N. Churchill, M.-H. Disatnik, L. Sun, D. Mochly-Rosen, Mitochondrial
import of PKCe is mediated by HSP90: a role in cardioprotection from ischaemia
and reperfusion injury, Cardiovasc. Res. 88 (2010) 83–92.
[30] A. Carpi, R. Menabo, N. Kaludercic, P. Pelicci, L.F. Di, M. Giorgio, The
cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial
role of mitochondrial ROS formation in ischemia/reperfusion injury, Biochim.
Biophys. Acta 1787 (2009) 744–780.
[31] A. Chacinska, C.M. Koehler, D. Milenkovic, T. Lithgow, N. Pfanner, Importing
mitochondrial proteins: machineries andmechanisms, Cell 138 (2009) 628–644.
[32] C.H. Chen, G.R. Budas, E.N. Churchill, M.H. Disatnik, T.D. Hurley, D. Mochly-Rosen,
Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart,
Science 321 (2008) 1493–1495.
[33] L. Chen, H. Hahn, G. Wu, C.-H. Chen, T. Liron, D. Schechtman, G. Cavallaro, L.
Banci, Y. Guo, R. Bolli, G.W. Dorn, D. Mochly-Rosen, Opposing cardioprotective
actions and parallel hypertrophic effects of dPKC and ePKC, Proc. Natl. Acad. Sci.
98 (2001) 11114–11119.
[34] E.N. Churchill, M.H. Disatnik, D. Mochly-Rosen, Time-dependent and ethanol-
induced cardiac protection from ischemia mediated by mitochondrial translo-
cation of varepsilonPKC and activation of aldehyde dehydrogenase 2, J. Mol. Cell.
Cardiol. 46 (2009) 278–284.
[35] S.J. Clarke, I. Khaliulin, M. Das, J.E. Parker, K.J. Heesom, A.P. Halestrap, Inhibition
of mitochondrial permeability transition pore opening by ischemic precondi-
tioning is probably mediated by reduction of oxidative stress rather than
mitochondrial protein phosphorylation, Circ. Res. 102 (2008) 1082–1090.
[36] A.D. Costa, K.D. Garlid, Intramitochondrial signaling—interactions among
mitoKATP, PKC{epsilon}, ROS, and MPT, Am. J. Physiol. Heart Circ. Physiol. 295
(2008) H874–H882.
[37] A.D.T. Costa, K.D. Garlid, I.C. West, T.M. Lincoln, J.M. Downey, M.V. Cohen, S.D.
Critz, Protein kinase G transmits the cardioprotective signal from cytososl to
mitochondria, Circ. Res. 97 (2005) 329–336.
[38] A.D.T. Costa, C.L. Quinlan, A. Andrukhiv, I.C. West, M. Jaburek, K.D. Garlid, The
direct physiological effects of mitoKATP opening on heart mitochondria, Am. J.
Physiol. Heart Circ. Physiol. 290 (2006) H406–H415.
[39] E.E. Craig, D.A. Hood, Inﬂuence of aging on protein import into cardiac
mitochondria, Am. J. Physiol. Heart Circ. Physiol. 41 (1997) H2983–H2988.
[40] E.R. Dabkowski, W.A. Baseler, C.L. Williamson, M. Powell, T.T. Razunguzwa, J.C.
Frisbee, J.M. Hollander, Mitochondrial dysfunction in the type 2 diabetic heart is
1293K. Boengler et al. / Biochimica et Biophysica Acta 1813 (2011) 1286–1294associated with alterations in spatially distinct mitochondrial proteomes, Am. J.
Physiol. Heart Circ. Physiol. 299 (2010) H529–H540.
[41] E.R. Dabkowski, C.L. Williamson, V.C. Bukowski, R.S. Chapman, S.S. Leonard, C.J.
Peer, P.S. Callery, J.M. Hollander, Diabetic cardiomyopathy-associated dysfunc-
tion in spatially distinct mitochondrial subpopulations, Am. J. Physiol. Heart Circ.
Physiol. 296 (2009) H359–H369.
[42] D.K. Das, N. Maulik, M. Sato, P.S. Ray, Reactive oxygen species function as second
messenger during ischemic preconditioning of heart, Mol. Cell. Biochem. 196
(1999) 59–67.
[43] S. Das, R. Wong, N. Rajapakse, E. Murphy, C. Steenbergen, Glycogen synthase
kinase 3 inhibition slows mitochondrial adenine nucleotide transport and
regulates voltage-dependent anion channel phosphorylation, Circ. Res. 103
(2008) 983–991.
[44] O.M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to
mitochondria, Nature 456 (2008) 605–610.
[45] F. Di Lisa, P. Bernardi, A CaPful of mechanisms regulating the mitochondrial
permeability transition, J. Mol. Cell. Cardiol. 46 (2009) 775–780.
[46] F. Di Lisa, M. Canton, R. Menabo, N. Kaludercic, P. Bernardi, Mitochondria and
cardioprotection, Heart Fail. Rev. 12 (2007) 249–260.
[47] F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabo, M. Giorgio, Mitochondrial pathways
for ROS formation and myocardial injury: the relevance of p66(Shc) and
monoamine oxidase, Basic Res. Cardiol. 104 (2009) 131–139.
[48] K.S. Dimmer, L. Scorrano, (De) constructing mitochondria: what for? Physiology
21 (2006) 233–241.
[49] W. Dröge, Free radicals in the physiological control of cell function, Physiol. Rev.
82 (2001) 47–95.
[50] T. Endo, K. Yamano, Multiple pathways for mitochondrial protein trafﬁc, Biol.
Chem. 390 (2009) 723–730.
[51] A.C. Fan, M.K. Bhangoo, J.C. Young, Hsp90 functions in the targeting and outer
membrane translocation steps of Tom70-mediated mitochondrial import, J. Biol.
Chem. 281 (2006) 33313–33324.
[52] I. Fridovich, Superoxide radical and superoxide dismutases, Annu. Rev. Biochem.
64 (1995) 97–112.
[53] B.N. Fuglesteg, N. Suleman, C. Tiron, T. Kanhema, L. Lacerda, T.V. Andreasen, M.N.
Sack, A.K. Jonassen, O.D. Mjos, L.H. Opie, S. Lecour, Signal transducer and
activator of transcription 3 is involved in the cardioprotective signalling
pathway activated by insulin therapy at reperfusion, Basic Res. Cardiol. 103
(2008) 444–453.
[54] M. Giorgio, E. Migliaccio, F. Orsini, D. Paolucci, M. Moroni, C. Contursi, G. Pelliccia,
L. Luzi, S. Minucci, M. Marcaccio, P. Pinton, R. Rizzuto, P. Bernardi, F. Paolucci, P.G.
Pelicci, Electron transfer between cytochrome c and p66(Shc) generates reactive
oxygen species that trigger mitochondrial apoptosis, Cell 122 (2005) 221–233.
[55] L. Gomez, M. Paillard, H. Thibault, G. Derumeaux, M. Ovize, Inhibition of
GSK3beta by postconditioning is required to prevent opening of the mitochon-
drial permeability transition pore during reperfusion, Circulation 117 (2008)
2761–2768.
[56] M.D. Goodman, S.E. Koch, G.A. Fuller-Bicer, K.L. Butler, Regulating RISK: a role for
JAK-STAT signaling in postconditioning? Am. J. Physiol. Heart Circ. Physiol. 295
(2008) H1649–H1656.
[57] R.A. Gottlieb, R.S. Carreira, Autophagy in health and disease. 5. Mitophagy as a
way of life, Am. J. Physiol. Heart Circ. Physiol. 299 (2010) C203–C210.
[58] D.J. Gough, A. Corlett, K. Schlessinger, J. Wegrzyn, A.C. Larner, D.E. Levy,
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Sci-
ence 324 (2009) 1713–1716.
[59] M.O. Gray, J.S. Karliner, D. Mochly-Rosen, A selective e-protein kinase c
antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell
death, J. Biol. Chem. 272 (1997) 30945–30951.
[60] J.Y. Grey, M.K. Connor, J.W. Gordon, M. Yano, M. Mori, D.A. Hood, Tom20-
mediated mitochondrial protein import in muscle cells during differentiation,
Am. J. Physiol. Heart Circ. Physiol. 279 (2000) C1393–C1400.
[61] D.H. Guo, T. Nguyen, M. Ogbi, H. Tawﬁk, G.C. Ma, Q.L. Yu, R.W. Caldwell, J.A.
Johnson, Protein kinase C-epsilon coimmunoprecipitates with cytochrome
oxidase subunit IV and is associated with improved cytochrome-c oxidase
activity and cardioprotection, Am. J. Physiol. Heart Circ. Physiol. 293 (2007)
H2219–H2230.
[62] M. Hamblin, D.B. Friedman, S. Hill, R.M. Caprioli, H.M. Smith, M.F. Hill, Alterations
in the diabetic myocardial proteome coupled with increased myocardial
oxidative stress underlies diabetic cardiomyopathy, J. Mol. Cell. Cardiol. 42
(2007) 884–895.
[63] D.J. Hausenloy, G. Baxter, R. Bell, H.E. BØtker, S.M. Davidson, J. Downey, G.
Heusch, M. Kitakaze, S. Lecour, R. Mentzer, M.M. Mocanu, M. Ovize, R. Schulz, R.
Shannon, M. Walker, G. Walkinshaw, D.M. Yellon, Translating novel strategies
for cardioprotection: the HatterWorkshop Recommendations, Basic Res. Cardiol.
105 (2010) 677–686.
[64] F.R. Heinzel, Y. Luo, X. Li, K. Boengler, A. Buechert, D. García-Dorado, F. Di Lisa, R.
Schulz, G. Heusch, Impairment of diazoxide-induced formation of reactive
oxygen species and loss of cardioprotection in connexin 43 deﬁcient mice, Circ.
Res. 97 (2005) 583–586.
[65] G. Heusch, K. Boengler, R. Schulz, Cardioprotection: nitric oxide, protein kinases,
and mitochondria, Circulation 118 (2008) 1915–1919.
[66] G. Heusch, K. Boengler, R. Schulz, Inhibition of mitochondrial permeability
transition pore opening: the holy grail of cardioprotection, Basic Res. Cardiol.
105 (2010) 151–154.
[67] G. Heusch, A. Büchert, S. Feldhaus, R. Schulz, No loss of cardioprotection by
postconditioning in connexin 43-deﬁcient mice, Basic Res. Cardiol. 101 (2006)
354–356.[68] J.M. Hollander, K.M. Lin, B.T. Scott, W.H. Dillmann, Overexpression of PHGPx and
HSP60/10 protects against ischemia/reoxygenation injury, Free Rad. Biol. Med.
35 (2003) 742–751.
[69] K. Inagaki, H.S. Hahn, G.W. Dorn II, D. Mochly-Rosen, Additive protection of the
ischemic heart ex vivo by combined treatment with d-protein kinase C inhibitor
and e-Protein kinase C activator, Circulation 108 (2003) 369–875.
[70] M. Jaburek, A.D. Costa, J.R. Burton, C.L. Costa, K.D. Garlid, Mitochondrial PKC
epsilon and mitochondrial ATP-sensitive K+channel copurify and coreconsti-
tute to form a functioning signaling module in proteoliposomes, Circ. Res. 99
(2006) 878–883.
[71] M. Juhaszova, D.B. Zorov, S.-H. Kim, S. Pepe, Q. Fu, K.W. Fishbein, B.D. Ziman, S.
Wang, K. Ytrehus, C.L. Antos, E.N. Olson, S.J. Sollott, Glycogen synthase kinase-3β
mediates convergence of protection signaling to inhibit the mitochondrial
permeability transition pore, J. Clin. Invest. 113 (2004) 1535–1549.
[72] M. Juhaszova, D.B. Zorov, Y. Yaniv, H.B. Nuss, S. Wang, S.J. Sollott, Role of glycogen
synthase kinase-3beta in cardioprotection, Circ. Res. 104 (2009) 1240–1252.
[73] L.G. Kevin, A.K.S. Camara, M.L. Riess, E. Novalija, D.F. Stowe, Ischemic precondition-
ing alters real-time measure of O2 radicals in intact hearts with ischemia and
reperfusion, Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H566–H574.
[74] J.E. Kokoszka, K.G. Waymire, S.E. Levy, J.E. Sligh, J. Cai, D.P. Jones, G.R. MacGregor,
D.C. Wallace, The ADP/ATP translocator is not essential for the mitochondrial
permeability transition pore, Nature 427 (2004) 461–465.
[75] C. Kupatt, R. Hinkel, J. Horstkotte, M. Deiβ, M.-L. von Brühl, M. Bilzer, P.
Boekstegers, Selective retroinfusion of GSH and cariporide attenuates myocar-
dial ischemia–reperfusion injury in a preclinical pig model, Cardiovasc. Res. 61
(2004) 530–537.
[76] S. Lau, N. Patnaik, R. Sayen, R. Mestril, Simultaneous overexpression of two stress
proteins in rat cardiomyocytes and myogenic cells confers protection against
ischemia-induced injury, Circulation 96 (1997) 2287–2294.
[77] E.J. Lesnefsky, B. Tandler, J. Ye, T.J. Slabe, J. Turkaly, C.L. Hoppel, Myocardial
ischemia decreases oxidative phosphorylation through cytochrome oxidase in
subsarcolemmal mitochondria, Am. J. Physiol. Heart Circ. Physiol. 273 (1997)
H1544–H1554.
[78] K.M. Lin, J.M. Hollander, V.Y. Kao, B. Lin, L. Macpherson, W.H. Dillmann, Myocyte
protection by 10 kD heat shock protein (Hsp10) involves the mobile loop and
attenuation of the Ras GTP-ase pathway, FASEB J. 18 (2004) 1004–1006.
[79] K.M. Lin, B. Lin, I.Y. Lian, R. Mestril, I.E. Schefﬂer, W.H. Dillmann, Combined and
individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes
protects mitochondrial function and prevents apoptotic cell deaths induced by
simulated ischemia-reoxygenation, Circulation 103 (2001) 1787–1792.
[80] G.S. Liu, M.V. Cohen, D. Mochly-Rosen, J.M. Downey, Protein kinase C-e is
responsible for the protection of preconditioning in rabbit cardiomyocytes,
J. Mol. Cell. Cardiol. 31 (1999) 1937–1948.
[81] G. Lu, H.K. Haider, S. Jiang, M. Ashraf, Sca-1+ stem cell survival and engraftment
in the infarcted heart: dual role for preconditioning-induced connexin-43,
Circulation 119 (2009) 2587–2596.
[82] G. Lu, H.K. Haider, A. Porollo, M. Ashraf, Mitochondria speciﬁc transgenic
overexpression of connexin-43 stimulates preconditioning induced cytoprotec-
tion of stem cells, Cardiovasc. Res. 88 (2010) 277–286.
[83] C. Maack, B. O'Rourke, Excitation–contraction coupling and mitochondrial
energetics, Basic Res. Cardiol. 102 (2007) 369–392.
[84] J.A. MacKenzie, R.M. Payne, Mitochondrial protein import and human health and
disease, Biochim. Biophys. Acta 1772 (2007) 509–523.
[85] T. Miki, T. Miura, H. Hotta, M. Tanno, T. Yano, T. Sato, Y. Terashima, A. Takada, S.
Ishikawa, K. Shimamoto, Endoplasmic reticulum stress in diabetic hearts
abolishes erythropoietin-induced myocardial protection by impairment of
phospho-glycogen synthase kinase-3 beta-mediated suppression of mitochon-
drial permeability transition, Diabetes 58 (2009) 2863–2872.
[86] D.G. Millar, G.C. Shore, Signal anchor sequence insertion into the outer
mitochondrial membrane. Comparison with porin and the matrix protein
targeting pathway, J. Biol. Chem. 271 (1996) 25823–25829.
[87] E. Miro-Casas, M. Ruiz-Meana, E. Agullo, S. Stahlhofen, A. Rodriguez-Sinovas, A.
Cabestrero, I. Jorge, I. Torre, J. Vazquez, K. Boengler, R. Schulz, G. Heusch, D.
Garcia-Dorado, Connexin43 in cardiomyocyte mitochondria contributes to
mitochondrial potassium uptake, Cardiovasc. Res. 83 (2009) 747–756.
[88] J.A. Muraski, M. Rota, Y. Misao, J. Fransioli, C. Cottage, N. Gude, G. Esposito, F.
Delucchi, M. Arcarese, R. Alvarez, S. Siddiqi, G.N. Emmanuel, W.Wu, K. Fischer, J.J.
Martindale, C.C. Glembotski, A. Leri, J. Kajstura, N. Magnuson, A. Berns, R.M.
Beretta, S.R. Houser, E.M. Schaefer, P. Anversa, M.A. Sussman, Pim-1 regulates
cardiomyocyte survival downstream of Akt, Nat. Med. 13 (2007) 1467–1475.
[89] E. Murphy, C. Steenbergen, Preconditioning: the mitochondrial connection,
Annu. Rev. Physiol. 69 (2007) 51–67.
[90] M.P. Murphy, How mitochondria produce reactive oxygen species, Biochem. J.
417 (2009) 1–13.
[91] C.E. Murry, R.B. Jennings, K.A. Reimer, Preconditioning with ischemia: a delay of
lethal cell injury in ischemic myocardium, Circulation 74 (1986) 1124–1136.
[92] A.C. Newton, Protein kinase C: poised to signal, Am. J. Physiol. Endocrinol. Metab.
298 (2010) E395–E402.
[93] M. Nishihara, T. Miura, T. Miki, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, K.
Ohori, A. Takahashi, K. Shimamoto, Erythropoietin affords additional cardiopro-
tection to preconditioned hearts by enhanced phsphorylation of glycogen
synthase kinase-3β, Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H748–H755.
[94] M. Nishihara, T. Miura, T. Miki, M. Tanno, T. Yano, K. Naitoh, K. Ohori, H. Hotta, Y.
Terashima, K. Shimamoto, Modulation of the mitochondrial permeability
transition pore complex in GSK-3beta-mediated myocardial protection, J. Mol.
Cell. Cardiol. 43 (2007) 564–570.
1294 K. Boengler et al. / Biochimica et Biophysica Acta 1813 (2011) 1286–1294[95] Y. Nishino, I.G. Webb, S.M. Davidson, A.I. Ahmed, J.E. Clark, S. Jacquet, A.M. Shah,
T. Miura, D.M. Yellon, M. Avkiran, M.S. Marber, Glycogen synthase kinase-3
inactivation is not required for ischemic preconditioning or postconditioning in
the mouse, Circ. Res. 103 (2008) 307–314.
[96] Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, K. Shimamoto,
Opening of mitochondrial KATP channel occurs downstream of PKC-e activation
in the mechanism of preconditioning, Am. J. Physiol. Heart Circ. Physiol. 283
(2002) H440–H447.
[97] S.B. Ong, D.J. Hausenloy, Mitochondrial morphology and cardiovascular disease,
Cardiovasc. Res. 88 (2010) 16–29.
[98] S.B. Ong, S. Subrayan, S.Y. Lim, D.M. Yellon, S.M. Davidson, D.J. Hausenloy,
Inhibiting mitochondrial ﬁssion protects the heart against ischemia/reperfusion
injury, Circulation 121 (2010) 2012–2022.
[99] M. Ovize, G.F. Baxter, F. Di Lisa, P. Ferdinandy, D. Garcia-Dorado, D.J. Hausenloy,
G. Heusch, J. Vinten-Johansen, D.M. Yellon, R. Schulz, Postconditioning and
protection from reperfusion injury: where do we stand? Cardiovasc. Res. 87
(2010) 406–423.
[100] T. Pain, X.-M. Yang, S.D. Critz, Y. Yue, A. Nakano, G.S. Liu, G. Heusch,M.V. Cohen, J.M.
Downey, Opening ofmitochondrial KATP channels triggers the preconditioned state
by generating free radicals, Circ. Res. 87 (2000) 460–466.
[101] G. Paradies, G. Petrosillo, M. Pistolese, N. Di Venosa, A. Federici, F.M. Ruggiero,
Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart.
Involvement of reactive oxygen species and cardiolipin, Circ. Res. 94 (2004)
53–59.
[102] C. Penna, M.G. Perrelli, S. Raimondo, F. Tullio, A. Merlino, F. Moro, S. Geuna, D.
Mancardi, P. Pagliaro, Postconditioning induces an anti-apoptotic effect and
preserves mitochondrial integrity in isolated rat hearts, Biochim. Biophys. Acta
1787 (2009) 794–801.
[103] P. Ping, Y. Zhang, X.-L. Tang, S. Manchikalapudi, X. Cao, R. Bolli, Ischemic
preconditioning induces selective translocation of protein kinase C isoforms e
and n in the heart of conscious rabbits without subcellular redistribution of total
protein kinase C activity, Circ. Res. 81 (1997) 404–414.
[104] C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T.T.
Cung, E. Bonnefoy, D. Angoulvant, C. Macia, F. Raczka, C. Sportouch, G. Gahide, G.
Finet, X. Andre-Fouet, D. Revel, G. Kirkorian, J.-P. Monassier, G. Derumeaux, M.
Ovize, Effect of cyclosporine on reperfusion injury in acute myocardial infarction,
N. Engl. J. Med. 359 (2008) 473–481.
[105] H.M. Piper, S. Kasseckert, Y. Abdallah, The sarcoplasmic reticulum as the primary
target of reperfusion protection, Cardiovasc. Res. 70 (2006) 170–173.
[106] E. Robin, R.D. Guzy, G. Loor, H. Iwase, G.B. Waypa, J.D. Marks, T.L. Hoek, P.T.
Schumacker, Oxidant stress during simulated ischemia primes cardiomyocytes
for cell death during reperfusion, J. Biol. Chem. 282 (2007) 19133–19143.
[107] A. Rodriguez-Sinovas, K. Boengler, A. Cabestrero, P. Gres, M. Morente, M. Ruiz-
Meana, I. Konietzka, E. Miró, A. Totzeck, G. Heusch, R. Schulz, D. Garcia-Dorado,
Translocation of connexin 43 to the inner mitochondrial membrane of
cardiomyocytes through the heat shock protein 90-dependent TOM pathway
and its importance for cardioprotection, Circ. Res. 99 (2006) 93–101.
[108] M.G. Rosca, E.J. Vazquez, J. Kerner, W. Parland, M.P. Chandler, W. Stanley, H.N.
Sabbah, C.L. Hoppel, Cardiac mitochondria in heart failure: decrease in
respirasomes and oxidative phosphorylation, Cardiovasc. Res. 80 (2008) 30–39.
[109] D. Rottlaender, K. Boengler, M. Wolny, G. Michels, J. Endres-Becker, L.J. Motloch,
A. Schwaiger, A. Buechert, R. Schulz, G. Heusch, U.C. Hoppe, Connexin 43 acts as a
cytoprotective mediator of signal transduction by stimulating mitochondrial
KATP channels in mouse cardiomyocytes, J. Clin. Invest. 120 (2010) 1441–1453.
[110] M. Ruiz-Meana, C. Fernandez-Sanz, D. Garcia-Dorado, The SR-mitochondria
interaction: a new player in cardiac pathophysiology, Cardiovasc. Res. 88 (2010)
30–39.
[111] A.T. Saurin, D.J. Pennington, N.J.H. Raat, D.S. Latchman, M.J. Owen, M.S. Marber,
Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size
reduction that follows ischaemic preconditioning of isolated buffer-perfused
mouse hearts, Cardiovasc. Res. 55 (2002) 672–680.
[112] R. Schulz, K. Boengler, A. Totzeck, Y. Luo, D. Garcia-Dorado, G. Heusch, Connexin
43 in ischemic pre- and postconditioning, Heart Fail. Rev. 12 (2007) 261–266.
[113] R. Schulz, P. Gres, A. Skyschally, A. Duschin, S. Belosjorow, I. Konietzka, G.
Heusch, Ischemic preconditioning preserves connexin 43 phosphorylation
during sustained ischemia in pig hearts in vivo, FASEB J. 17 (2003) 1355–1357.
[114] X. Shen, S.R. Zheng, V. Thongboonkerd, M. Xu, W.M. Pierce, J.B. Klein, P.N.
Epstein, Cardiac mitochondrial damage and biogenesis in a chronic model of
type 1 diabetes, Am. J. Physiol. Endocrinol. Metab. 287 (2004) E896–E905.
[115] V. Sivaraman, D.J. Hausenloy, S. Kolvekar, M. Hayward, J. Yap, D. Lawrence, S.C.
Di, D.M. Yellon, The divergent roles of protein kinase C epsilon and delta in
simulated ischaemia–reperfusion injury in human myocardium, J. Mol. Cell.
Cardiol. 46 (2009) 758–764.
[116] A. Skyschally, P. van Caster, K. Boengler, P. Gres, J. Musiolik, D. Schilawa, R.
Schulz, G. Heusch, Ischemic postconditioning in pigs: no causal role for RISK
activation, Circ. Res. 104 (2009) 15–18.[117] R.M. Smith, N. Suleman, L. Lacerda, L.H. Opie, S. Akira, K.R. Chien, M.N. Sack,
Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning,
Cardiovasc. Res. 63 (2004) 611–616.
[118] G. Söhl, K. Willecke, Gap junctions and the connexin protein family, Cardiovasc.
Res. 62 (2004) 228–232.
[119] J.L. Solan, P.D. Lampe, Connexin43 phosphorylation: structural changes and
biological effects, Biochem. J. 419 (2009) 261–272.
[120] J. Stumpner, A. Redel, A. Kellermann, C.A. Lotz, C.A. Blomeyer, T.M. Smul, F. Kehl,
N. Roewer, M. Lange, Differential role of Pim-1 kinase in anesthetic-induced and
ischemic preconditioning against myocardial infarction, Anesthesiology 111
(2009) 1257–1264.
[121] N. Suleman, S. Somers, R. Smith, L.H. Opie, S.C. Lecour, Dual activation of STAT-3
and Akt is required during the trigger phase of ischaemic preconditioning,
Cardiovasc. Res. 79 (2008) 127–133.
[122] M. Takahashi, A. Chesley, D. Freyssenet, D.A. Hood, Contractile activity-induced
adaptations in the mitochondrial protein import system, Am. J. Physiol. Heart
Circ. Physiol. 274 (1998) C1380–C1387.
[123] S. Tamareille, N. Ghaboura, F. Treguer, D. Khachman, A. Croue, D. Henrion, A.
Furber, F. Prunier, Myocardial reperfusion injury management: erythropoietin
compared with postconditioning, Am. J. Physiol. Heart Circ. Physiol. 297 (2009)
H2035–H2043.
[124] S.W. Taylor, E. Fahy, B. Zhang, G.M. Glenn, D.E. Warnock, S.Wiley, A.N. Murphy, S.
P. Gaucher, R. Capaldi, B.W. Gibson, S.S. Gosh, Characterization of the human
heart mitochondrial proteome, Nat. Biotechnol. 21 (2003) 281–286.
[125] H. Tong, K. Imahashi, C. Steenbergen, E. Murphy, Phosphorylation of glycogen
synthase kinase-3β during preconditioning through a phosphatidylinositol-3-
kinase-dependent pathway is cardioprotective, Circ. Res. 90 (2002) 374–376.
[126] A. Totzeck, K. Boengler, A. van de Sand, I. Konietzka, P. Gres, D. Garcia-Dorado, G.
Heusch, R. Schulz, No impact of protein phosphatases on connexin 43
phosphorylation in ischemic preconditioning, Am. J. Physiol. Heart Circ. Physiol.
295 (2008) H2106–H2112.
[127] I.V. Turko, F. Murad, Quantitative protein proﬁling in heart mitochondria from
diabetic rats, J. Biol. Chem. 278 (2003) 35844–35849.
[128] J.F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol. 552
(2003) 335–344.
[129] M. Uecker, R. Da Silva, T. Grampp, T. Pasch, M.C. Schaub, M. Zaugg, Translocation
of protein kinase C isoforms to subcellular targets in ischemic and anesthetic
preconditioning, Anesthesiology 99 (2003) 138–147.
[130] T.L. Vanden Hoek, L.B. Becker, Z.-H. Shao, C.-Q. Li, P.T. Schumacker, Precondition-
ing in cardiomyocytes protects by attenuating oxidant stress at reperfusion, Circ.
Res. 86 (2000) 541–548.
[131] T.L. Vanden Hoek, C. Li, Z. Shao, P.T. Schumacker, L.B. Becker, Signiﬁcant levels of
oxidants are generated by isolated cardiomyocytes during ischemia prior to
reperfusion, J. Mol. Cell. Cardiol. 29 (1997) 2571–2583.
[132] J. Vinten-Johansen, Z.-Q. Zhao, A.J. Zatta, H. Kin, M.E. Halkos, F. Kerendi,
Postconditioning. A new link in nature's armor against myocardial ischemia–
reperfusion injury, Basic Res. Cardiol. 295 (2005) 295–310.
[133] W. Voos, H. Martin, T. Krimmer, N. Pfanner, Mechanisms of protein translocation
into mitochondria, Biochim. Biophys. Acta 1422 (1999) 235–254.
[134] J. Wegrzyn, R. Potla, Y.J. Chwae, N.B. Sepuri, Q. Zhang, T. Koeck, M. Derecka, K.
Szczepanek, M. Szelag, A. Gornicka, A. Moh, S. Moghaddas, Q. Chen, S. Bobbili, J.
Cichy, J. Dulak, D.P. Baker, A. Wolfman, D. Stuehr, M.O. Hassan, X.Y. Fu, N.
Avadhani, J.I. Drake, P. Fawcett, E.J. Lesnefsky, A.C. Larner, Function of
mitochondrial Stat3 in cellular respiration, Science 323 (2009) 793–797.
[135] C.L. Williamson, E.R. Dabkowski, W.H. Dillmann, J.M. Hollander, Mitochondria
protection from hypoxia/reoxygenation injury with mitochondria heat shock
protein 70 overexpression, Am. J. Physiol. Heart Circ. Physiol. 294 (2008)
H249–H256.
[136] R. Wong, A.M. Aponte, C. Steenbergen, E. Murphy, Cardioprotection leads to
novel changes in the mitochondrial proteome, Am. J. Physiol. Heart Circ. Physiol.
298 (2010) H75–H91.
[137] A.J. Zatta, H. Kin, G. Lee, N. Wang, R. Jiang, R. Lust, J.G. Reeves, J. Mykytenko, R.A.
Guyton, Z.Q. Zhao, J. Vinten-Johansen, Infarct-sparing effect of myocardial
postconditioning is dependent on protein kinase C signalling, Cardiovasc. Res. 70
(2006) 315–324.
[138] J. Zhang, X. Li, M. Mueller, Y. Wang, C. Zong, N. Deng, T.M. Vondriska, D.A. Liem, J.I.
Yang, P. Korge, H. Honda, J.N. Weiss, R. Apweiler, P. Ping, Systematic characteriza-
tion of the murine mitochondrial proteome using functionally validated cardiac
mitochondria, Proteomics 8 (2008) 1564–1575.
[139] Z.-Q. Zhao, J.S. Corvera, M.E. Halkos, F. Kerendi, N.-P. Wang, R.A. Guyton, J.
Vinten-Johansen, Inhibition of myocardial injury by ischemic postconditioning
during reperfusion: comparison with ischemic preconditioning, Am. J. Physiol.
Heart Circ. Physiol. 285 (2003) H579–H588.
[140] H. Zou, Y.C. Li, H.S. Liu, X.D. Wang, An APAF-1 center dot cytochrome c
multimeric complex is a functional apoptosome that activates procaspase-9,
J. Biol. Chem. 274 (1999) 11549–11556.
